Loading the state's markets…
Loading the state's markets…
Loading the market…
Medicare market size, surgeons and outlook to 2030
Medicare fee-for-service aortic endografts (EVAR/TEVAR) cases in Iowa: reported (2020, the pandemic year, left out of the line), then forecast with its 80% range. One year ahead, this procedure’s market forecast has been off by 10% on average (139 state-years, 2020–2024): read it as a direction with a margin.
| Year | Surgeons | Medicare FFS | Advantage share |
|---|---|---|---|
| 2019 | 3 | 163 | 24% |
| 2020 | 1 | 152 | 27% |
| 2021 | 0 | 137 | 30% |
Endovascular abdominal and thoracic aortic repair. Professional codes (what the surgeon bills): CPT 34701, 34702, 34703, 34704, 34705, 34706, 33880, 33881; the hospital bills MS-DRG 268, 269, 213, 209.
Surgeons and fee-for-service cases are from CMS’s Medicare Physician & Other Practitioners files, counted where the surgeon billed; state totals include the cases CMS leaves out of the surgeon-level file (under 11 patients). All Medicare adds patients in Medicare Advantage at the state’s enrollment share; all payers scales Medicare by its share of the procedure nationally. The forecast carries cases per resident 65+ forward with the Census projection of residents 65+. How the numbers are made · Data sources
The 10 busiest do 100% of the cases CMS names in Iowa; 1 surgeons do 80% of them.
MedaRep names every one, ranked by volume, with their practice, hospitals, trend, forecast and which device companies already engage with them.
| Surgeons | Medicare FFS | Growth since 2019 | Per 1,000 | Out of hospital | Forecast | |
|---|---|---|---|---|---|---|
| Peripheral arterial intervention | 8 | 1,121−12%/yr | −12%/yr | 2.40.6× | 11% | 1,490 in 2030+4.9%/yr |
| Superficial venous ablation |
Aortic endografts (EVAR/TEVAR) in every state, and its device makers · Every procedure market in Iowa · Every state · Compare with Ohio
| 2024 |
| 169 |
| 40% |
| 2025 est. | ≈ 170 | – |
| 2026 est. | ≈ 180 | – |
| 2022 | 2 | 154 | 34% |
| 2023 | 1 | 165 | 38% |
| 2024 | 1 | 169 | 40% |
| 2025 from claims | – | 170 137–200 | 41% |
| 2026 forecast | – | 179 141–225 | 40% |
| 2027 forecast | – | 186 138–246 | 40% |
| 2028 forecast | – | 192 136–265 | 41% |
| 2029 forecast | – | 199 135–285 | 41% |
| 2030 forecast | – | 206 135–306 | 42% |
In 2025, 88% inpatient hospital, 12% hospital outpatient.
| −7.4%/yr |
| 0.4 |
| 0% |
| 600 in 2030+1.1%/yr |
| Michigan | 0 | 381−11%/yr | −11%/yr | 0.5 | 0% | 370 in 2030−0.6%/yr |
| Missouri | 5 | 372−9.1%/yr | −9.1%/yr | 0.6 | 0% | 340 in 2030−1.6%/yr |
| Indiana | 4 | 350−7.1%/yr | −7.1%/yr | 0.5 | 0% | 380 in 2030+1.5%/yr |
| Wisconsin | 1 | 197−8.5%/yr | −8.5%/yr | 0.4 | 0% | 270 in 2030+5.7%/yr |
| Minnesota | 0 | 187−8.9%/yr | −8.9%/yr | 0.4 | 0% | 190 in 2030+0.2%/yr |
| Kansas | 3 | 178−7.8%/yr | −7.8%/yr | 0.4 | 0% | 160 in 2030−1.9%/yr |
| 16 |
| 1,064−7.3%/yr |
| −7.3%/yr |
| 2.30.7× |
| 98% |
| 970 in 2030−1.5%/yr |
| Dialysis access | 15 | 691−12%/yr | −12%/yr | 1.60.3× | 11% | 760 in 2030+1.5%/yr |
| Carotid revascularization | 11 | 376−4.9%/yr | −4.9%/yr | 0.80.7× | 0% | 380 in 2030+0.3%/yr |
| Thrombectomy, IVC filters & venous stents | 1 | 3090%/yr | 0%/yr | 0.70.5× | 0% | 490 in 2030+8.2%/yr |
Share of the cases CMS names by surgeon, by where they billed. Open one for its ranking.
W L Gore & Associates leads with 51% of company spending on these surgeons in 2025, −18 pts on 2024.
In 2025, 5 companies reported engagement with Iowa’s surgeons worth $14K in consulting, speaking, meals and travel tied to these products, about $14K per surgeon billing it. Royalties are left out.
FDA, last 12 months: 36 clearances and approvals in the category, 2 recalled product lines (1 Class I). A recall is a public FDA notice, not a finding of fault.
Which surgeons each company engages, and the dollars reported, are in the ranking. Open Payments shows the payments companies reported. It suggests engagement, not which devices a surgeon uses, and is not evidence of wrongdoing. Every company in the category.